18 May 2026
LONDON, UK--(BUSINESS WIRE)--Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting.
Read More
16 Feb 2026
London, UK - 16 February 2026 - Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapy for the treatment...
11 Nov 2025
London, UK - November 11, 2025 — Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the...
1 Nov 2024
LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...
14 Mar 2024
LONDON, UK, March 14, 2024 – Prokarium announces they have been awarded a UK Research and Innovation (UKRI) Engineering Biology...
7 Feb 2024
London, UK – February 7, 2024 – Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic...
2 Nov 2023
London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...
9 Feb 2023
London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...
9 Jan 2023
LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...
19 Oct 2022
LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
2 Mar 2022
LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
26 Jan 2022
LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
11 Nov 2021
LONDON, UK – November 11, 2021– Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today...
2 Nov 2021
LONDON, UK – November 2, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
12 Oct 2021
London / Amsterdam – October 12, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial...
5 Oct 2021
LONDON, UK – October 5, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
27 Jul 2021
LONDON, UK – July 27, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
26 Mar 2021
Entervax is a novel bivalent oral vaccine against enteric fever, currently in a phase 1 trial with the...
27 Oct 2020
Industry veteran, Hyam Levitsky, MD, appointed to Prokarium’s Board of Directors – Financing will support the clinical...
14 Jul 2020
Prokarium receives Notice of Allowance for US patent covering Entervax, an oral bivalent vaccine against enteric fever.
28 Apr 2020
Prokarium advances its oncology programme for bladder cancer signing an exclusive option agreement with CHUV.
6 Jan 2020
Prokarium welcomes Hyam Levitsky and David Holden as new advisors.
26 Nov 2019
MHRA accepts a phase I trial with Prokarium's vaccine against enteric fever.
8 Oct 2019
Wellcome Trust funds Prokarium's vaccine against enteric fever.
10 Jan 2019
Prokarium moves offices and laboratories to LBIC.
1 Sept 2018
Prokarium expands its team to develop a new microbial immunotherapy for solid tumours.
26 Feb 2018
Prokarium closes $10 million Series A round to develop thermostable vaccines.
CONTACT
Privacy policy
Cookie policy
Prokarium 2026 © All Rights Reserved